BICO (formerly Cellink) / Neuracle Neuroscience

Neuracle Neuroscience, headquartered in Waltham, Massachusetts, is a neurodiagnostics company developing clinical-grade wireless EEG monitoring systems designed for long-term ambulatory brain monitoring. The company's flagship product, the NeuroCap, is a disposable pre-gelled EEG cap that standardizes electrode placement and dramatically reduces setup time compared to conventional EEG systems, which traditionally require trained technicians and lengthy preparation procedures. By eliminating the need for manual gel application and individual electrode positioning, NeuroCap also significantly reduces infection risk, making it well-suited for deployment in high-acuity environments such as intensive care units. The system is engineered to support continuous, high-quality neural signal acquisition across clinical indications including epilepsy diagnosis, seizure monitoring, and broader neurological disease management.

Neuracle Neuroscience has secured over $30 million in Series B funding, reflecting strong investor confidence in its approach to modernizing EEG infrastructure within clinical settings. The company operates within the BICO Group ecosystem, a global life science tools and bioconvergence company formerly known as Cellink, which has strategically expanded into neurotechnology through targeted acquisitions and partnerships. This backing has enabled Neuracle to advance its clinical validation efforts and pursue regulatory pathways that support adoption across hospital systems and ambulatory care networks. Their progress positions them as an emerging commercial-stage company within the neurodiagnostics segment, with growing traction among neurologists, intensivists, and clinical researchers.

Neuracle Neuroscience represents a meaningful shift in how the neurotech industry approaches the accessibility and scalability of brain monitoring technology. Traditional EEG systems have long been constrained by complexity, cost, and the need for specialized personnel, creating significant bottlenecks in timely neurological assessment. By delivering a standardized, disposable solution that preserves clinical-grade signal fidelity, Neuracle directly addresses one of the most persistent barriers to widespread EEG utilization in both acute and outpatient settings. As the neurodiagnostics market expands with growing demand for continuous brain monitoring and earlier neurological intervention, Neuracle's platform is well-positioned to influence clinical workflows, improve patient outcomes, and help establish new standards of care across the neurology landscape.